Annual sales objective achieved
+12.3% organic growth at constant scope and currency
Avignon, 25 January 2012 - NATUREX, NATUREX, world leader in specialty plant-based ingredients, presents its annual consolidated sales the year 2011:
| K€ IFRS Unaudited data |
2011 | 2010 | Var. % | Var. % at constant currency |
| 1st quarter | 64,021 |
51,611 |
+24.0% | +17.5% |
| 2nd quarter | 63,904 | 60,478 | +5.7% |
+9.3% |
| 3rd quarter | 63,226 |
58,472 | +8.1% |
+12.0% |
| 4th quarter (excluding BURGUNDY) | 59,718 | 55,746 | +7.1% | +11.1% |
| Annual sales Constant scope |
250,869 | 226,307 | +10.9% | +12.3% |
| Integration of BURGUNDY | 2,700 | - | - | |
| 4th quarter (new scope) |
62,418 | 55,746 | +12.0% | |
| Annual sales New scope |
253,568 | 226,307 | +12.0% |
| K€ IFRS Unaudited data |
2011* | 2010 | Share of turnover % |
Var. % |
| Food & Beverage | 153,412 | 137,108 | 60.5% | +11.9% |
| Nutrition & Health | 84,496 | 75,523 | 33.3% | +11.9% |
| Personal Care | 3,008 | 2,709 | 1.2% | +11.0% |
| Miscellaneous and toll extraction |
12,652 | 10,967 | 5.0% | +15.4% |
| K€ IFRS Unaudited data |
2011* | 2010 | Share of turnover % |
Var. % |
| Europe / Africa | 132,013 |
117,718 | 52.1% | +12.1% |
| Americas | 92,708 |
84,107 | 36.6% | +10.2% |
| Asia / Oceania | 28,847 | 24,482 | 11.4% |
+17.8% |
The emerging markets of Eastern Europe, Asia, Latin America, Africa and the Middle East which represented 14% of the Group’s sales over 2011, compared with less than 10% one year previously, offer highly promising development prospects.
“We are very satisfied with this excellent year of growth, marked by the positive orientation of all of our activities and geographic zones. The integration of BURGUNDY is now on the road to completion and our teams are working actively to quickly develop the commercial synergies.” declared Jacques Dikansky, Chief Executive Officer and Founder of NATUREX.
“With our strengthened geographic positioning, the highly favourable acceptance of our new product ranges and our industrial and scientific expertise, we are confident in our ability to continue to outperform the future growth of our markets.”
Next publications
- Annual results 2011 28 March 2012
Forthcoming events
- Midcap Event Brussels 29-30 March 2012
- SFAF analysts meeting - Paris 2 April 2012
Naturex has been listed since October 1996 on NYSE Euronext Paris, Compartment B (MidCaps).
Number of shares comprising the capital: 7,705,580
6,718,272 ordinary shares (ISIN FR0000054694)
987,308 preferred shares (ISIN FR0010833251)
Naturex is a component of the CAC Small and Gaïa indexes.
Naturex is eligible for "long only" Deferred Settlement Service (SRD).
Naturex has implemented a Sponsored Level I American Depositary Receipt (ADR) program,
which trades on over-the-counter market in the United States under symbol NTUXY.
TICKER: NRX - Reuters : NATU.PA - Bloomberg : NRX:FP - DR Symbol: NTUXY
About Naturex
NATUREX is a global leader in specialty plant-based natural ingredients.
The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.
NATUREX’s head office is based in Avignon, France. The company employs more than 1,000 people with high-performance manufacturing operations across 13 sites in Europe (France, Italy, Spain, the United Kingdom, Switzerland), as well as in Morocco, the United States, Brazil and Australia. It also has a global presence through a dedicated network of sales offices in 18 countries (France, Italy, Spain, the United Kingdom, Belgium, Germany, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, the United States, Canada, Brazil and Mexico).
NATUREX's development is supported by positive underlying trends linked to a fast-growing demand for natural products and its capacity to provide manufacturers customised solutions to meet the requirements of their end consumers. The Group's strength lies in its positioning with specific products which constitute niche markets, supported by strong sourcing capacity and sustained research & development.
Jacques Dikansky
President and Chief Executive Officer
Tel.: +33 (0)4 90 23 96 89
Thierry Lambert
Vice-President and Chief Financial Officer
Tel.: +33 (0)4 90 23 96 89
Carole Alexandre
Investor Relations
Tel.: +33 (0)4 90 23 78 28
Anne Catherine Bonjour
Actus Finance Press Relations
Tel.: +33 (0)1 53 67 36 93